Aevi Genomic Medicine, Inc. (NASDAQ:GNMX)‘s stock had its “hold” rating reissued by research analysts at Jefferies Group LLC in a report released on Thursday. They presently have a $1.50 price target on the biotechnology company’s stock. Jefferies Group LLC’s price objective suggests a potential upside of 19.05% from the company’s current price.

A number of other research analysts have also recently issued reports on GNMX. ValuEngine cut Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Needham & Company LLC lowered their price objective on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, August 16th.

Aevi Genomic Medicine (NASDAQ GNMX) traded down 0.79% during midday trading on Thursday, reaching $1.26. The company had a trading volume of 210,901 shares. The company has a 50-day moving average of $1.28 and a 200-day moving average of $1.70. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $6.89. The stock’s market capitalization is $46.76 million.

TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/30/aevi-genomic-medicine-inc-gnmx-stock-rating-reaffirmed-by-jefferies-group-llc.html.

Several hedge funds have recently bought and sold shares of the company. TIAA CREF Investment Management LLC raised its stake in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 13,966 shares during the last quarter. Teachers Advisors LLC purchased a new position in shares of Aevi Genomic Medicine in the fourth quarter worth $204,000. Birchview Capital LP raised its stake in shares of Aevi Genomic Medicine by 88.2% in the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 60,000 shares during the last quarter. Northern Capital Management LLC raised its stake in shares of Aevi Genomic Medicine by 317.9% in the second quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 80,675 shares during the last quarter. Finally, LMR Partners LLP purchased a new position in shares of Aevi Genomic Medicine in the second quarter worth $149,000. Hedge funds and other institutional investors own 20.82% of the company’s stock.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Stock Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related stocks with our FREE daily email newsletter.